AURINIA PHARMACEUTICALS INC news, videos and press releases
For more news please use our advanced search feature.
AURINIA PHARMACEUTICALS INC - More news...
AURINIA PHARMACEUTICALS INC - More news...
- Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
- Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
- Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
- Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
- LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
- Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
- Aurinia Announces 2023 Annual General Meeting Results
- Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
- Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
- Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
- ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
- Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
- Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
- Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
- Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
- Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
- Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
- Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
- Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
- Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aurinia Announces PTAB Has Terminated Inter Partes Review
- Thinking about buying stock in First Wave BioPharma, GasLog Partners, Canoo, Aurinia Pharmaceuticals, or Rocket Lab USA?
- Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
- Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
- Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference